Impact Of 5-Alpha Reductase Inhibitor Use On Prostate Cancer Risk At The Time Of Urology Referral.

James T Kearns,Justin T. Matulay,William E. Anderson,Timothy C. Hetherington,Claud Grigg,Jason Zhu,Kris E. Gaston,Stephen Boyd Riggs,Earle F Burgess,Peter E Clark

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览6

暂无评分

摘要

226Background: 5-alpha reductase inhibitors (5-ARIs) are commonly used medications for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. One of the consequences ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要